Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort

Key facts

Sponsor

Beijing Chest Hospital

Intervention

Bedaquiline(drug)

Enrollment

186 target

Eligibility

18-70 years · All sexes

Timeline

2023 – 2026

Study locations (30)

• Beijing Chest Hospital affiliated to Capital Medical University, Beijing, Beijing Municipality, China
• Changsha Central Hospital, Changsha, China, China
• Anhui Chest Hospital, Hefei, China, China
• Jiamusi Tumor Hospital, Jiamusi, China, China
• Shandong public health clinical center, Shandong, China, China
• Xi'an Chest Hospital, Xi'an, China, China
• The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China, China
• Hebei Chest Hospital, Shijiazhuang, Hebei, China
• Harbin Chest Hospital, Harbin, Heilongjiang, China
• Infectious Disease Hospital of Hulunbuir, Hulunbuir, Inner Mongolia, China
• Qingdao Chest Hospital, Qingdao, Shandong, China
• Taiyuan Fourth People's Hospital, Taiyuan, Shanxi, China
• The 8th Medical Center of Chinese Pla General Hospital, Beijing, China
• Hunan Province Chest Hospital, Changsha, China
• Chongqing Public Heath Treatment Center, Chongqing, China
• +15 more locations on ClinicalTrials.gov

Collaborators

National Medical Center for Infectious Diseases

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Primary pulmonary tuberculosis

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07484490
  Effects of the Active Cycle of Breathing Technique With and Without Balloon Blowing Therapy in Tuberculosis
  Riphah International University
• RECRUITINGPHASE3NCT07209761
  A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis
  Otsuka Pharmaceutical Development & Commercialization, Inc.
• RECRUITINGPHASE2NCT07170800
  A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets
  WestVac Biopharma Co., Ltd.
• RECRUITINGPHASE2NCT06192160
  Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
  National Institute of Allergy and Infectious Diseases (NIAID)
• RECRUITINGPHASE2NCT06748937
  A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With Ethionamide
  TASK Applied Science
• ACTIVE NOT RECRUITINGNANCT07186478
  I-FALMIN Albumin Supplement for Patients With Pulmonary Tuberculosis
  Hasanuddin University
• ACTIVE NOT RECRUITINGPHASE3NCT06649721
  Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort
  Huashan Hospital
• RECRUITINGPHASE4NCT06476210
  The Safety and Efficacy of BDL(Bedaquiline Plus Delamanid Plus Linezolid) Regimen in Subjects With Pulmonary Infection of Multi-drug Resistant Tuberculosis (MDR-TB) or Rifampicin-Resistant Tuberculosis (RR-TB)
  Beijing Chest Hospital

See all trials for Primary pulmonary tuberculosis →